팝업레이어 알림

팝업레이어 알림이 없습니다.

DuChemBio, No.1 Radiopharmaceutical company in Korea with cutting-edge technology

  • DuChemBio,
    No.1 Radiopharmaceutical company
    in Korea with cutting-edge technology

  • DuChemBio,
    No.1 Radiopharmaceutical company
    in Korea with cutting-edge technology

  • DuChemBio,
    No.1 Radiopharmaceutical company
    in Korea with cutting-edge technology

  • DuChemBio,
    No.1 Radiopharmaceutical company
    in Korea with cutting-edge technology

  • DuChemBio,
    No.1 Radiopharmaceutical company
    in Korea with cutting-edge technology

Our Mission

Developing new Radiopharmaceuticals for cancer diagnosis & treatment,
and achieving successful commercialization locally & globally

Core Strategy in each growth level

No. 1 Radiopharmaceutical infrastructure and network (2009 ~ 2012)

  • The only GMP standard facilities in Korea even before GMP implementation
  • Operation of the five major Radiopharmaceutical Centers covering the entire country
  • Initial cooperation with Asan Medical Center (AMC) for FP-CIT development

Core Strategy in each growth level

The only Open Platform in Korea for Diagnostic Radiopharmaceutical development and commercialization (2013 ~ 2018)

  • Establishment of human resources and global network for new drug development, conduct of clinical trial and new drug approval
  • Biggest Radiopharmaceutical market share for FDG, FP-CIT, and Neuraceq
  • Successful ‘Technology Evaluation’ for transferring to KOSDAQ supported by ‘Open Innovation Strategy’ in creating and expanding the market for radiopharmaceuticals in the field of Oncology & Neurology

Core Strategy in each growth level

Market Leader in Southeast Asia providing new Radiopharceutical package, technology, and know-how (2019 ~ onwards)

  • Good investment result of the first Philippine commercial manufacturing center and acquisition of SEA market entrance knowlege
  • The first-mover for new drug packages with innovative technology and know-how in Southeast Asia
  • GMP consulting and services and expertise recognized by local and international networks

Core Strategy in each growth level

Licensing Agreement for international expansion & Portfolio Evolution (2021 ~ Future)

  • Secure new growth engine and economy of scale through the merger after corporate divion of Carecamp, Inc
  • Build up of Alzheimer’s disease portfolio such as Vyzamyl
  • Further development of innovative theranostics for radiopharmaceuticals in the field of Oncology & Neurology

그누보드5
Address 6,7F, 81, Wausan-ro, Mapo-gu, Seoul, Republic of Korea [04041]
Tel 02 332 4868 Fax 02 323 3437

Copyright © 2021, DuchemBio, Co., Ltd. All Rights Reserved